The researchers at University Hospital of Muenster think so. I can't really tell from the data so far. I don't have any good historical controls to compare this to. Is 13 months of survival in these heavily treated advanced cancer patients a lot, a little, or what we'd expect anyway? We definitely need a randomized clinical trial with survival as an endpoint. Many
open questions too about
when in the progression process it ought to be used, given that PSMA occurs more frequently on more advanced cancer cells.
/pcnrv.blogspot.com/2017/10/does-lu-177-psma-617-increase-survival.html